Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$354K Buy
11,097
+209
+2% +$6.59K 0.2% 20
2017
Q1
$353K Hold
10,888
0.19% 23
2016
Q4
$336K Sell
10,888
-448
-4% -$13.7K 0.18% 22
2016
Q3
$364K Hold
11,336
0.2% 22
2016
Q2
$379K Buy
11,336
+3,107
+38% +$99.2K 0.21% 22
2016
Q1
$231K Hold
8,229
0.13% 29
2015
Q4
$252K Hold
8,229
0.15% 27
2015
Q3
$245K Hold
8,229
0.16% 24
2015
Q2
$262K Hold
8,229
0.13% 26
2015
Q1
$272K Hold
8,229
0.13% 26
2014
Q4
$243K Buy
8,229
+290
+4% +$8.31K 0.12% 28
2014
Q3
$223K Buy
7,939
+209
+3% +$5.87K 0.12% 29
2014
Q2
$218K Hold
7,730
0.13% 26
2014
Q1
$236K Buy
7,730
+117
+2% +$3.49K 0.14% 23
2013
Q4
$221K Hold
7,613
0.13% 27
2013
Q3
$207K Sell
7,613
-175
-2% -$4.76K 0.13% 26
2013
Q2
$207K Buy
+7,788
New +$215K 0.14% 25

Other funds holding PFE

Kinsight LLC's PFE Position: Q2 2017 in Review

Kinsight LLC increased its Pfizer (PFE) stake by 1.9% in Q2 2017, buying an estimated $6.59K and bringing the position to 11,097 shares worth $354K. The position accounts for 0.2% of the portfolio, ranked #20.

Kinsight LLC first reported a position in PFE in Q2 2013 and has held it in 17 quarters since. The position peaked at $379K in Q2 2016. 2,049 funds tracked by Wall St. Rank hold PFE as of Q2 2017.

  • Kinsight LLC held 11,097 shares of Pfizer worth $354K as of Q2 2017.
  • Kinsight LLC bought 209 Pfizer shares in Q2 2017, an estimated $6.59K.
  • Pfizer made up 0.2% of Kinsight LLC's portfolio in Q2 2017, its #20 holding.
  • Kinsight LLC first reported a position in Pfizer in Q2 2013 and has held it in 17 quarters since.
  • Kinsight LLC's Pfizer position peaked at $379K in Q2 2016.
  • 2,049 funds tracked by Wall St. Rank held Pfizer as of Q2 2017.

Based on Kinsight LLC's 13F filing for Q2 2017, filed 24 Jul 2017.